Table 1 |
||
|
Treatment with rhAPC: survival rate, risk of death and side effects |
||
| Placebo n = 840 |
rhAPC n = 850 |
|
|
|
||
| 28 day mortality |
30.83% |
24.77% |
| Relative risk of death |
Not applicable |
19.43% reduction |
| Survival odds |
Not applicable |
38.1% increase |
| Serious bleed event |
2.0% |
3.5% (P = 0.06) |
|
|
||
|
Smith Critical Care 2001 5:72 doi:10.1186/cc990 |
||